A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Life expectancy of at least 12 weeks
Adequate hematologic and end organ function
Histologic documentation of locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy is ineffective, intolerable, or considered inappropriate; or for which a clinical trial of an investigational agent is recognized standard of care
Tumor specimen availability
Measurable disease according to RECIST v1.1
You may not be if
Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
Malignancies other than disease under study within 5 years prior to D1 of C1
Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
History of leptomeningeal disease
History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
History of autoimmune disease
Positive human immunodeficiency virus test result
Active hepatitis B, hepatitis C, or tuberculosis
Severe infection within 4 weeks prior to D1 of C1
Prior allogeneic bone marrow or solid organ transplantation
Significant cardiovascular disease
Known clinically significant liver disease
Clareo Health | A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors
